The study of antiviral drugs targeting SARS-CoV-2 nucleocapsid and spike proteins through large-scale compound repurposing

Contributing to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) clinical treatment, a drug library encompassing approximately 3,142 clinical-stage or FDA-approved small molecules is profiled to identify the candidate therapeutic inhibitors targeting nucleocapsid protein (N) and spike protein (S) of SARS-CoV-2. 16 screened candidates with higher binding affinity are evaluated via virtual screening. Comparing to those under trial/temporarily used antivirus drugs (i.e., umifenovir, lopinavir), ceftriaxone, cefotaxime, and cefuroxime show higher binding affinities to the N-terminal domain of N protein (N-NTD), C-terminal domain of N protein (N-CTD), and receptor-binding domain of S protein (S-RBD). Cefotaxime and cefuroxime have high binding affinities towards S-RBD with angiotensin-converting enzyme 2 (ACE2) complex via influence the critical interface sites at the interface of S-RBD (Arg 403 , Tyr 453 , Trp 495 , Gly 496 , Phe 497 , Asn 501 and Tyr 505 ) and ACE2 (Asn 33 , His 34 , Glu 37 , Asp 38 , Lys 353 , Ala 386 , Ala 387 , Gln 388 , Pro 389 , Phe 390 and Arg 393 ) complex.

Abstract licence: CC BY-NC-ND

1. 5.

   Coronavirus Genomics and Bioinformatics Analysis · 2010

2. 7.

   Transient Oligomerization of the SARS-CoV N Protein – Implication for Virus Ribonucleoprotein Packaging · 2013

3. 16.

   RCSB Protein Data Bank: Sustaining a living digital data resource that enables breakthroughs in scientific research and biomedical education · 2017

4. 27.

   A pneumonia outbreak associated with a new coronavirus of probable bat origin · 2020

5. 28.

   Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro · 2020

6. 37.

   Structure-based drug designing and immunoinformatics approach for SARS-CoV-2 · 2020

7. 39.

   SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses · 2020

8. 42.

   The SARS-CoV-2 nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein · 2021

37 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.